Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Other financing activities: 2019-2023

  • Summit Therapeutics' Other financing activities was N/A to $80,000 in Q2 2023 from the same period last year, while for Jun 2023 it was $689,000, marking a year-over-year change of. This contributed to the annual value of $619,000 for FY2023, which is 457.66% up from last year.
  • As of Q2 2023, Summit Therapeutics' Other financing activities stood at $80,000, which was down 85.16% from $539,000 recorded in Q1 2023.
  • Summit Therapeutics' Other financing activities' 5-year high stood at $539,000 during Q1 2023, with a 5-year trough of -$41,000 in Q4 2021.
  • In the last 3 years, Summit Therapeutics' Other financing activities had a median value of $80,000 in 2023 and averaged $148,600.
  • Its Other financing activities has fluctuated over the past 5 years, first plummeted by 185.42% in 2021, then spiked by 105.56% in 2022.
  • Summit Therapeutics' Other financing activities (Quarterly) stood at $333,000 in 2019, then tumbled by 85.59% to $48,000 in 2020, then plummeted by 185.42% to -$41,000 in 2021, then spiked by 105.56% to $111,000 in 2022, then reached $80,000 in 2023.
  • Its Other financing activities was $80,000 in Q2 2023, compared to $539,000 in Q1 2023 and $111,000 in Q3 2022.